IBRX

ImmunityBio's stock experienced significant volatility over the past six months. In November 2025, the company reported strong Q3 financial results with a 434% increase in product revenue. In January 2026, preliminary full-year revenue was announced at $113 million, a 700% increase year-over-year, and ANKTIVA received approval in Saudi Arabia. February 2026 saw a 700% increase in net product revenue and conditional marketing authorization in Europe, causing a stock surge. In March 2026, the stock dropped 20% after an FDA warning letter regarding misleading statements in advertising. In April 2026, the company responded to the FDA and reported preliminary Q1 revenue of $44.2 million, a 168% increase. In May 2026, the company presented new data and reported Q1 revenue of $44.2 million, but the stock declined due to bearish sentiment and class-action lawsuits.